Trial Profile

A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS 01 Eye Drops in Subjects with Diabetic Macular Edema

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary)
Indications Diabetic macular oedema
Focus Registrational; Therapeutic Use
Acronyms DIAMOND 2
Sponsors Oculis Pharma

Most Recent Events

15 Apr 2025 According to an Oculis Pharma media release, the topline data anticipated in Q2 2026.
10 Apr 2025 Status changed from recruiting to active, no longer recruiting.
10 Apr 2025 According to an Oculis Pharma media release, Company to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-person and virtual R&D Day on Tuesday, April 15.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com